SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 2, 1999, Pages 582-589

  Portier, Marielle ^a   Rinaldi Carmona, Murielle ^a   Pecceu, Florence ^a   Combes, Thérèse ^a   Poinot Chazel, Caroline ^a   Calandra, Bernard ^a   Barth, Francis ^a   Le Fur, Gérard ^a   Casellas, Pierre ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID RECEPTOR ANTAGONIST; N (1 ENDO 1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL)PYRAZOLE 3 CARBOXAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; DRUG EFFECT; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADENYLATE CYCLASE; ANIMALS; BORNANES; CHO CELLS; CRICETINAE; CYCLIC AMP; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; PYRAZOLES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0033035659     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. 9-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem 271:9902-9905.
2. Bouaboula M, Bourrié B, Rinaldi-Carmona M, Shire D, Le Fur G and Casellas P (1995a) Stimulation of cannabinoid receptor CB1 induces krox24 expression in human astrocytoma cells. J Biol Chem 270:13973-13980.
3. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand JP, Le Fur G and Casellas P (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1: Evidence for a new model for receptor/ligand interactions. J Biol Chem 272:22330-22339.
4. Bouaboula M, Poinot-Chazel C, Bourrié B, Canat X, Calandra B, Rinaldi-Carmona M, Le Fur G and Casellas P (1995b) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312: 637-641.
5. Bouaboula M, Poinot-Chazel C, Marchand J, Canat X, Bourrié B, Rinaldi-Carmona M, Calandra B, Le Fur G and Casellas P (1996) Signalling pathway associated with stimulation of CB2 peripheral cannabinoid receptor: Involvement of both mitogen-activated protein kinase and induction of Krox24 expression. Eur J Biochem 237:704-711.
6. Chidiac P, Hebert TE, Valiquette M, Dennis M and Bouvier M (1994) Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 45:490-499.
7. Childers SR and Deadwyler SA (1996) Role of cyclic AMP in the actions of cannabinoid receptors. Biochem Pharmacol 52:819-827.
8. Das SK, Paria BC, Chakraborty I and Dey SK (1995) Cannabinoid ligand-receptor signalling in the mouse uterus. Proc Natl Acad Sci USA 92:4332-4336.
9. Derocq JM, Segui M, Marchand J, Le Fur G and Casellas P (1995) Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett 369: 177-182.
10. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (Washington DC) 258:1946-1949.
11. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-450.
12. Felder CC, Nielsen A, Briley EM, Palkovits M, Priller J, Axelrod J, Nguyen DN, Richardson JM, Riggin RM, Koppel GA, Paul SM and Becker GW (1996) Isolation and measurement of the endogenous cannabinoid receptor agonist anandamide in brain and peripheral tissues of human and rat. FEBS Lett 396:213-235.
13. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G and Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61.
14. Glass M and Dragunow M (1995) Induction of the Krox 24 transcription factor in striatosomes by a cannabinoid agonist. Neuroreport 6:241-244.
15. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR and Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936.
16. Hollister LE (1988) Marijuana and immunity. J Psychoactive Drugs 20:3-8.
17. Jung M, Calassi R, Rinaldi-Carmona M, Chardenot P, Le Fur G, Soubrié P and Oury-Donat F (1997) Characterization of CB1 receptors on rat neuronal cell cultures: Binding and functional studies using the selective receptor antagonist SR 141716. J Neurochem 68:402-409.
18. Kaminsky NE (1996) Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signalling cascade and altered gene expression. Biochem Pharmacol 52:1133-1140.
19. Kenakin T (1996) The classification of seven transmembrane receptors in recombinant systems. Pharmacol Rev 48:413-463.
20. Landsman RS, Burkey TH, Consroe P, Roeske WR and Yamara HI (1997) SR 141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 334:R1-R2.
21. Lee M, Yang KH and Kaminski NE (1995) Effects of putative cannabinoid receptor ligands anandamide and 2-arachidonyl-glycerol on immune function in B6C3F1 mouse splenocytes. J Pharmacol Exp Ther 275:529-536.
22. Lynn AB and Herkenham M (1994) Localization of cannabinoid receptors and non-saturable high density cannabinoid binding sites in peripheral tissues of the rat: Implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 268:1612-1622
23. Mailleux P, Verslype M, Preud'homme X and Vanderhaeghen J (1994) Activation of multiple transcription factor genes by tetrahydrocannabinol in rat forebrain. Neuroreport 5:1265-1268.
24. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (Lond) 346:561-564.
25. McEwan DJ and Milligan G (1996a) Up-regulation of a constitutively active form of the (32-adrenoceptor by sustained treatment with inverse agonists but not antagonists. FEBS Lett 399:108-112.
26. 2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells. Mol Pharmacol 50:1479-1486.
27. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Shatz A, Gopher AR, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J and Vogel Z (1995) Identification of an endogenous 2-monoglyceride present in canine gut that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90.
28. Milligan G, Bond RA and Lee M (1995) Inverse agonism: Pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol Sci 16:10-13.
29. Miloux B and Lupker JH (1994) Rapid isolation of highly productive recombinant Chinese hamster ovary cell lines. Gene 149:341-344.
30. Munro S, Thomas KL and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature (Lond) 365:61-65.
31. Poinot-Chazel C, Portier M, Bouaboula M, Vita N, Pecceu F, Gully D, Monroe JG, Maffrand JP, Le Fur G and Casellas P (1996) Activation of mitogen-activated protein kinase couples neurotensin receptor stimulation to induction of the primary response gene Krox24. Biochem J 320:145-151.
32. Rao RV, Roettger BF, Hadac EM and Miller LJ (1997) Roles of cholecystokinin receptor phosphorylation in agonist-stimulated desensitization of pancreatic acinar cells and receptor-bearing hamster ovary cholecystokinin receptor cells. Mol Pharmacol 51:185-192.
33. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Brelière JC and Le Fur G (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650.
34. Roettger BF, Ghanekar D, Rao RV, Toledo C, Yingling J, Pinon D and Miller LJ (1997) Antagonist-stimulated internalization of the G protein-coupled cholecystokin receptor. Mol Pharmacol 51:357-362.
35. Samama P, Cotecchia S, Costa T and Lefkowitz RJ (1993) A mutation-induced activated state of the β-adrenergic receptor: Extending the ternary complex model. J Biol Chem 90:10365-10369.
36. Sanchez C, Velasco G and Guzman M (1997) Metabolic stimulation of mouse spleen lymphocytes by low doses of delta9-tetrahydrocannabinol. Life Sci 60:1709-1717.
37. Scheer A and Cotecchia S (1997) Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation. J Recept Signal Transd Res 17:57-73.
38. Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessègue B, Bonnin-Cabanne O, Le Fur G, Caput D and Ferrara P (1996) Molecular cloning expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta 1307:132-136.
39. Slipetz DM, O'Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y, Guay D, Labelle M and Metters KM (1995) Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 48:352-361.
40. Smit MJ, Leurs R, Alewijnse AE, Blauw J, Van Nieuw Amerongen GP, Van de Vrede Y, Roovers E and Timmerman H (1996) Inverse agonism of histamine H2 antagonists accounts for upregulation of spontaneously active histamine H2 receptors. Proc Natl Acad Sci USA 93:6802-6807.
41. Stella N, Schweitzer P and Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773-778.